Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional StudyHiroki Ishihara, Toshio Takagi, Takashi Ikeda et al.|Targeted Oncology|2023Cited by 19
Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective StudyHiroki Ishihara, Kazunari Tanabe, Yuki Nemoto et al.|Targeted Oncology|2021Cited by 9